Company profile: RefleXion
1.1 - Company Overview
Company description
- Provider of biologically-guided radiotherapy systems for patients with cancer, offering SCINTIX therapy that uses emissions from cancer cells to target and treat lung or bone tumors at any stage. Provides the RefleXion X1 platform delivering SCINTIX and CT-guided IMRT and SBRT with fan-beam kVCT imaging for superior patient localization, plus Limbus Contour integration to expedite radiotherapy planning.
Products and services
- RefleXion X1 platform: Clinical-grade dual-modality radiotherapy platform that delivers SCINTIX and CT-guided IMRT/SBRT, featuring fan-beam kVCT imaging for superior patient localization
- SCINTIX therapy: Biologically-guided radiotherapy system that harnesses cancer-cell emissions to target and treat lung or bone tumors across any cancer stage, enhancing localization via emitted signals
- Limbus Contour integration: AI-driven integration of Limbus AI’s automated contouring software into the RefleXion X1 treatment planning system, expediting radiotherapy planning processes with streamlined, automated contour generation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to RefleXion
AdnaGen
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic testing systems for medical and clinical research laboratories, offering AdnaTest kits with reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics, and focusing on genetic pre-disposition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdnaGen company profile →
Intact Medical
HQ: United States
Website
- Description: Provider of minimally invasive systems for volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intact Medical company profile →
F-star
HQ: United Kingdom
Website
- Description: Provider of novel bispecific antibody therapeutics focused on immuno-oncology and oncology, developing bispecific antibody products to improve the standard of care, with the ability to create and develop Fcab™ antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F-star company profile →
Tempest Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics that modulate anti-tumor pathways, including TPST-1120, an oral PPARα antagonist designed to inhibit fatty acid oxidation and inflammation with potential in hepatocellular, renal cell, and cholangiocarcinoma, and TPST-1495, an oral dual EP2/EP4 antagonist in Phase 1/1b combination studies to reduce tumor growth and immune suppression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tempest Therapeutics company profile →
Beacon Biomedical
HQ: United States
Website
- Description: Provider of easy, accurate, and affordable blood-based tests for earlier cancer detection, developing and commercializing waived test (LDT) solutions for healthcare practitioners and individuals. Offerings include BeScreened-CRC, a blood-based colorectal cancer screening test for adults 45+ who are unwilling or unable to undergo traditional screening methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beacon Biomedical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for RefleXion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to RefleXion
2.2 - Growth funds investing in similar companies to RefleXion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for RefleXion
4.2 - Public trading comparable groups for RefleXion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →